Impressive Bleeding Profile With Factor XI Inhibitor in AF
xFurther details from the phase 2b AZALEA trial with the factor XI inhibitor abelacimab (Anthos) show significant reductions in major and clinically relevant nonmajor bleeding compared with rivaroxaban for patients with AF; the risk of stroke was moderate to high. The trial was stopped earlier this year because of an “overwhelming” reduction in bleeding with …
